A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-07 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Musculoskeletal effects === Skeletal muscle tremor is the most common adverse effect of beta-agonists, and is more likely to be seen after oral administration than after inhalation. Tremor results from an imbalance between fast- and slow-twitch muscle groups of the extremities, and its severity varies greatly between individuals.
A Moscow court ordered the arrests of film producer Alexander Rodnyansky and theatre director Ivan Vyrypaev for "spreading false information" about the Russian army, with Vyrypaev additionally being placed on the Russian federal wanted list by the Interior Ministry. Both individuals had been living in exile for their opposition to the war in Ukraine. Another court sentenced opposition figure and anti-war activist Mikhail Krieger to seven years in prison on charges of justifying terrorism and inciting hatred with the threat of violence prior to the invasion. Prior to his sentencing, Krieger said that he was being prosecuted for his "anti-war and now openly pro-Ukrainian position". During a summit in Iceland, the Council of Europe approved a "Register of Damage" to document actions of Russian forces in Ukraine for future claims of compensation against Russia. The United States, which attended the summit as an observer, Canada and Japan also supported the register.
Aquaphor was developed in 1925 in the United States laboratories of Beiersdorf Inc. It was trademarked that year by Herman A. Metz, the company's president. In 1929, Beiersdorf sold the Aquaphor trademarks to Duke Laboratories to facilitate manufacturing in the country. In 1936, Aquaphor's first product offering was sold to doctors, pharmacists and hospitals in 5 lb. containers. Production was discontinued during World War II but resumed by Duke Laboratories in 1960. At that time, 1 lb cans and 2 oz tubes were sold to medical professionals. Beiersdorf repurchased the trademarks from Duke Laboratories in 1973. In 1982, the product was sold directly to consumers for the first time. The formulation was expanded in 1991 with the launch of "Advanced Therapy Healing Ointment", an addition to the original ointment. Beiersdorf further expanded the brand in the early 2000s, introducing baby products in 2003 and a lip repair line in 2011. In 2012, the brand launched globally in 25 other countries. In 2013, Aquaphor achieved the Good Housekeeping Seal.
== Mechanisms == The mechanism by which dedifferentiation occurs has not been completely illuminated. The pathways discussed below are found to be closely related to dedifferentiation and regeneration in some species. Because not one pathway has been elucidated as necessary for all dedifferentiation and regeneration, the mechanism may function differently in different species.
Sources: en.wikipedia.org
=== Quality === Semen quality is a measure of the ability of semen to accomplish fertilization. Thus, it is a measure of fertility in a man. It is the sperm in the semen that is the fertile component, and therefore semen quality involves both sperm quantity and sperm quality.
These frequent long treatments are often done at home while sleeping, but home dialysis is a flexible modality and schedules can be changed day to day, week to week. In general, studies show that both increased treatment length and frequency are clinically beneficial. Hemo-dialysis was one of the most common procedures performed in U.S. hospitals in 2011, occurring in 909,000 stays (a rate of 29 stays per 10,000 population).
==== Amputations ==== Save the Children reported 10 children a day in Gaza had lost their limbs, which would result in a lifetime of medical needs. A UNICEF spokesperson James Elder was quoted after returning from Gaza in mid-December 2023, that around 1,000 children had lost one or both legs since the 7 October attacks and the start of the war. According to the British doctor Ghassan Abu-Sittah, "This is the biggest cohort of pediatric amputees in history". In mid-December 2023, a teenager's amputation performed without anesthesia on her families kitchen table by her uncle who is a doctor went viral on social media. She and a sibling had climbed to the top of the building to call their father who is overseas before the building was reportedly struck by IDF tank fire, and she was rushed inside to her uncle. In early-January 2024, an 11-year-old speaking to reporters about her injuries which included an amputated leg and with the other severely injured expressed her hope in getting an artificial limb, and lamented how her life has become "ugly and sad" after the injury. Other children's stumps after amputation had to be re-opened after infections had set in. By June 2024, doctors in Gaza estimated as many as 3,000 children had lost limbs since October 2023. A WHO Emergency Medical Team coordinator also cautioned that due to lack of medical expertise and time, some of the amputations done were unnecessary or due to a time delay. The head of Humanity & Inclusion stated child amputees needed "immediate support" for prosthetics but that wasn't happening.
Sources: en.wikipedia.org
The Mark V initially used a single power source for the flashlight, sprinting, and oxygen supply; in Half-Life 2: Episode Two the flashlight was given a separate power source to improve gameplay. The symbol on Gordon's HEV suit is the lowercase Greek letter Lambda, λ. This symbol is used by scientists to denote the decay constant of radioactive elements (related to the half-life of an element). As well as appearing on Gordon's suit, the symbol replaces the letter "a" in the game title (Hλlf-Life) and is the name of the complex in the Black Mesa Research Facility where teleportation experiments are conducted in the first game. The Lambda symbol is also seen in Half-Life 2 as a marking of the human resistance, seen close to hidden supplies and on the armbands of better equipped resistance fighters.
=== Pars nervosa === Also called the neural lobe or posterior lobe, this region constitutes the majority of the posterior pituitary and is the storage site of oxytocin and vasopressin. Sometimes (incorrectly) considered synonymous with the posterior pituitary, the pars nervosa includes Herring bodies and pituicytes.
In the famous Monty Python "Spam" sketch Bromley was stated to be the location of the fictional Green Midget Café, where every item on the menu was composed of spam in varying degrees. In another Monty Python sketch, it was stated that all seven continents are visible from the top of the Kentish Times building in Bromley. The Bromley Contingent was the name given to the entourage that followed the Sex Pistols and helped popularise the punk movement. It was so called because many of its members were from Bromley, some of whom later became famous as musicians in their own right, like Siouxsie Sioux and Billy Idol. The 2018 comedy film, The Bromley Boys is set in Bromley and surroundings in the late 1960s and early 1970s. Based on a real-life memoir by Dave Roberts about following Bromley F.C., it includes many scenes filmed locally, although Crockenhill F.C. was used as a substitute for the Hayes Lane stadium. Guitarist Billy Jenkins, born in Bromley, released an album titled "Sounds like Bromley" in 1982 and another in 1997 titled "Still Sounds Like Bromley". In a BBC Radio 3 interview he said that "if Kent is the Garden of England then Bromley is one of the compost heaps". He then moved to Lewisham.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.